Nasdaq · Healthcare
Oncology Institute, Inc. (TOI)
As-reported financials and recent SEC filings for Oncology Institute, Inc., latest fiscal period FY2025. Every figure is pulled straight from the company’s EDGAR filings — no estimates.
Snapshot
Revenue
$502.7M
Net income
$-60.6M
Net margin
-12.1%
Diluted EPS
$-0.54
ROE
385.5%
P/E (TTM)
—
Market cap
$538.9M
Debt / equity
-4.9×
Income statement (as reported)
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | $502.7M | $393.4M | $324.2M | $252.5M | $203.0M |
| Gross profit | — | — | — | — | — |
| Operating income | $-36.1M | $-60.1M | $-77.0M | $-82.0M | $-45.9M |
| Net income | $-60.6M | $-64.7M | $-83.1M | $152,000 | $-10.9M |
| Diluted EPS | $-0.54 | $-0.71 | $-0.92 | $-0.21 | $-0.16 |
Source: company XBRL financial statements on SEC EDGAR.
Recent SEC filings
42026-06-24
View on EDGAR →8-K2026-06-18
View on EDGAR →42026-06-09
View on EDGAR →1442026-06-08
View on EDGAR →42026-06-05
View on EDGAR →42026-05-22
View on EDGAR →42026-05-22
View on EDGAR →42026-05-22
View on EDGAR →Go deeper on TOI
Search Oncology Institute, Inc.’s filings with cited answers, compare it against peers, build an operating model, and track it in your portfolio — all in one place.
Start freeData sourced from SEC EDGAR (public domain). Figures are as-reported and may be unaudited or restated; verify against the source filing before relying on them. Informational only — not investment advice.